Provided by Tiger Trade Technology Pte. Ltd.

INNOVENT BIO

86.100
+0.6000.70%
Volume:17.49M
Turnover:1.50B
Market Cap:149.38B
PE:161.75
High:86.950
Open:85.000
Low:83.500
Close:85.500
52wk High:109.100
52wk Low:36.600
Shares:1.74B
HK Float Shares:1.74B
Volume Ratio:1.29
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.532
ROE:5.01%
ROA:1.49%
PB:6.81
PE(LYR):161.75
PS:10.11

Loading ...

Innovent Biologics - Clarifies Not Engaged in Pursuing Such Transaction

THOMSON REUTERS
·
Mar 25

Innovent Biologics - All Conditions Precedent to Effectiveness of Strategic Collaboration Agreement Between Lilly and Co Satisfied

THOMSON REUTERS
·
Mar 25

JPMorgan Boosts Stake in Innovent Bio with Purchase of Approximately 497,800 Shares

Stock News
·
Mar 24

Innovent Phase 3 STAR trial shows efdamrofusp alfa meets primary endpoint in nAMD with 72.8% at Q16W dosing

Reuters
·
Mar 24

the Phase 3 Registration Star Study of Efdamrofusp Alfa (Ibi302) Met Its Primary Endpoint, Making It the First Self-Developed Extended-Interval Treatment for Namd in China

THOMSON REUTERS
·
Mar 24

Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat

Reuters
·
Mar 23

Innovent Announces First Participant Dosed of Ibi128 (Tigulixostat, Xoi) in Phase 3 Clinical Study

THOMSON REUTERS
·
Mar 23

Pop Mart, Laopu Gold Are Set to Post Triple-Digit Growth as They See Bright 2026

Tiger Newspress
·
Mar 20

China's Biopharma Sector Expected to Receive More Government Support -- Market Talk

Dow Jones
·
Mar 18

CMB International Foresees Accelerated Fundamental Improvement in China's Healthcare Sector, Recommends Buying Innovent Bio, 3SBIO, and Others

Stock News
·
Mar 17

Innovent Biologics board to review annual results and consider final dividend recommendation

Reuters
·
Mar 12

Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications

Deep News
·
Mar 06

Biopharma Stocks Rally as Sector Gains Strategic "Emerging Pillar" Status

Stock News
·
Mar 06

INNOVENT BIO (01801) Announces Monthly Return for February 2026

Bulletin Express
·
Mar 05

JPMorgan Chase Increases Stake in INNOVENT BIO (01801) by Approximately 408.6 Thousand Shares at HK$84.94 Per Share

Stock News
·
Mar 05

Morgan Stanley Reinitiates Coverage on Innovent Bio with "Overweight" Rating, Sees Biotech Catalysts Concentrated in Second Half

Stock News
·
Mar 04

Innovent Biologics Says Lymphoma Drug Bags China Nod for Additional Indication

MT Newswires Live
·
Mar 02

Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

THOMSON REUTERS
·
Mar 02

BRIEF-Innovent Biologics Says Jaypirca Received Approval By NMPA China

Reuters
·
Feb 27

Innovent Biologics, Inc. (1801) Announces NMPA Approval of Jaypirca for Recurrent CLL/SLL

Bulletin Express
·
Feb 27